Metabolic syndrome in neuroendocrine tumors of the gastrointestinal tract
https://doi.org/10.62546/3034-1477-2024-2-1-15-21
Abstract
Visceral obesity and metabolic syndrome are major risk factors for type 2 diabetes, cardiovascular disease and cancer. Data analyzing the relationship between metabolic syndrome and gastroenteropancreatic neuroendocrine neoplasms are extremely limited (Italian scientists made the greatest contribution to the study of this issue).
The study of the relationship between sporadic neuroendocrine tumors of the gastrointestinal tract (GEP NET) and metabolic syndrome deserves special attention.
The purpose of this article is to analyze the main works that are devoted to the assessment of metabolic syndrome and associated factors in neuroendocrine tumors of the gastrointestinal tract.
Solving the problems of clinical assessment of the presence of metabolic syndrome in neuroendocrine tumors of the gastrointestinal tract can potentially be important both for prognostic purposes and for the development of preventive measures.
In addition to reviewing the main studies devoted to the study of metabolic syndrome in neuroendocrine tumors of the gastrointestinal tract, in this article we present the results of our own research.
About the Authors
A. V. Androsova
St. Petersburg State University; City Clinical Oncology Dispensary
Russian Federation
Russian Federation
Androsova Aleksandra Valeryevna — post-graduate student; medical oncologist of Cancer Drug Therapy (Chemotherapeutic) Dept No. 10
Saint Petersburg
R. V. Orlova
St. Petersburg State University; City Clinical Oncology Dispensary
Russian Federation
Russian Federation
Orlova Rashida Vakhidovna — DM Sci (habil.), head of Dept of Oncology; chief specialist in clinical oncology
Saint Petersburg
N. P. Belyak
St. Petersburg State University; City Clinical Oncology Dispensary
Russian Federation
Russian Federation
Belyak Natalia Petrovna — PhD Med, associate professor at Dept of Oncology; head of Cancer Drug Therapy (Chemotherapeutic) Dept No. 10
Saint Petersburg
A. K. Ivanova
St. Petersburg State University
Russian Federation
Russian Federation
Ivanova Anastasia Konstantinovna — Cand. of Sci. (Med.), medical oncologist of Cancer Drug Therapy (Chemotherapeutic) Department No. 11
S. I. Kutukova
City Clinical Oncology Dispensary; Pavlov First Saint Petersburg State Medical University
Russian Federation
Russian Federation
Kutukova Svetlana Igorevna — DM Sci (habil.), professor at Dept of Maxillofacial Surgery, associate professor at Dept of Oncology; medical oncologist of Cancer Drug Therapy (Chemotherapeutic) Dept No. 10
References
1. Serebrennikova S.N., Guzovskaya E.V., Seminsky I.Zh. Pathophysiology of metabolic syndrome: textbook. Irkutsk: Publishing house IGMU, 2017. 52 p. (In Russ.).
2. Giudice A., Montella M., Boccellino M., Crispo A., D’Arena G., Bimonte S. et al. Epigenetic Changes Induced by Green Tea Catechins are Associated with Prostate Cancer // Curr. Mol. Med. 2017. Vol. 17, No. 6. Р. 405–420. doi: 10.2174/1566524018666171219101937.
3. Colao A., de Nigris F., Modica R., Napoli C. Clinical Epigenetics of Neuroendocrine Tumors: The Road Ahead // Front Endocrinol. 2020. Vol. 11. Р. 604341–604353. doi: 10.3389/fendo.2020.604341.
4. Vinik A.I., Gonzales M.R.C. New and emerging syndromes due to neuroendocrine tumors // Endocrinology and Metabolism Clinics. 2011. Vol. 40, No. 1. P. 19–63. doi: 10.1016/j.ecl.2010.12.010.
5. Santos A.P., Santos A.C., Castro C. et al. Visceral obesity and metabolic syndrome are associated with well-differentiated gastroenteropancreatic neuroendocrine tumors // Cancers. 2018. Vol. 10, No. 9. P. 293. doi: 10.3390/cancers10090293.
6. Barrea L., Muscogiuri G., Modica R. et al. Cardio-metabolic indices and metabolic syndrome as predictors of clinical severity of gastroenteropancreatic neuroendocrine tumors // Frontiers in Endocrinology. 2021. Vol. 12. P. 649496. doi: 10.3389/fendo.2021.649496.
7. Barrea L., Muscogiuri G., Pugliese G. et al. Chronotype: what role in the context of gastroenteropancreatic neuroendocrine tumors? // Journal of Translational Medicine. 2021. Vol. 19, No. 1. P. 324. doi: 10.1186/s12967-021-03010-1.
8. Pusceddu S., Vernieri C., Di Maio M. et al. Impact of diabetes and metformin use on enteropancreatic neuroendocrine tumors: Post hoc analysis of the CLARINET study // Cancers. 2021. Vol. 14, No. 1. P. 69. doi: 10.3390/cancers14010069.
9. Feola T., Puliani G., Sesti F. et al. Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a three-centric case-control study // Journal of Endocrinological Investigation. 2022. Vol. 45, No. 4. P. 849–857. doi: 10.1007/s40618-021-01715-0.
Review
For citations:
Androsova A.V., Orlova R.V., Belyak N.P., Ivanova A.K., Kutukova S.I. Metabolic syndrome in neuroendocrine tumors of the gastrointestinal tract. Clinical Case in Oncology. 2024;2(1):15-21. (In Russ.) https://doi.org/10.62546/3034-1477-2024-2-1-15-21
Views:
262
Email this article 